Clinical Trial

Biology of Juvenile Myoclonic Epilepsy

Study acronym: BIOJUME
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-01-12; most recent amendment 2025-08-28.
Trial Details
NCT Number NCT03400371
Lead Sponsor King's College London
Collaborators: King's College Hospital NHS Trust, Charles University, Czech Republic, Hopital Universitaire Robert-Debre, Vestre Viken Hospital Trust, The Hospital for Sick Children, Cardiff University, Odense University Hospital
Conditions Juvenile Myoclonic Epilepsy
Enrollment 1,000 participants
Start Date 2017-07-13
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-05